NASDAQ: LYRA - Lyra Therapeutics, Inc.

Rentabilität für sechs Monate: -31.96%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan Lyra Therapeutics, Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen Lyra Therapeutics, Inc.

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.

weitere details
The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 2020-05-01
ISIN US55234L1052
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://lyratherapeutics.com
Цена ао 6.13
Preisänderung pro Tag: +5.48% (0.1806)
Preisänderung pro Woche: +5.83% (0.18)
Preisänderung pro Monat: +0.2632% (0.19)
Preisänderung über 3 Monate: -28.3% (0.2657)
Preisänderung über sechs Monate: -31.96% (0.28)
Preisänderung pro Jahr: -96.36% (5.24)
Preisänderung über 3 Jahre: -95.81% (4.55)
Preisänderung über 5 Jahre: 0% (0.1905)
Preisänderung über 10 Jahre: 0% (0.1905)
Preisänderung seit Jahresbeginn: +0.7937% (0.189)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 159.19 1
P/BV 2.77 6
P/E 0 0
EV/EBITDA -3.87 0
Gesamt: 3.5

Effizienz

Name Bedeutung Grad
ROA, % -43.96 0
ROE, % -70.1 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.412 10
Gesamt: 10

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 29.83 4
Rentabilität Ebitda, % 295.45 10
Rentabilität EPS, % -51.03 0
Gesamt: 6.8
Weitere Details

Institutionen Volumen Aktie, %
Perceptive Advisors LLC 12757562 21.35
Nantahala Capital Management, LLC 8100436 13.56
Vestal Point Capital, LP 3000000 5.02
Point72 Asset Management, L.P. 3000000 5.02
Citadel Advisors Llc 2861255 4.79
Samsara BioCapital, LLC 2780261 4.65
VR Adviser, LLC 2575593 4.31
Rosalind Advisors, Inc. 1888720 3.16
PURA VIDA INVESTMENTS, LLC 1413242 2.37
Ikarian Capital, LLC 1254384 2.1

ETF Aktie, % Rentabilität für das Jahr, % Dividenden, %
iShares Micro-Cap ETF 0.00348 17.09 1.54048
iShares Russell 2000 Growth ETF 0.00096 38.04 0.6026
ProShares UltraPro Russell2000 0.0003 89.82 1.47873
ProShares Hedge Replication ETF 0.00008 5.92 1.47892
Vanguard Russell 2000 ETF 0 17.16 1.48801
Vanguard Russell 2000 Growth ETF 0 23.05 0.60264



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Dr. Harlan W. Waksal M.D. Executive Chairman 210.06k 1953 (72 Jahr)
Dr. Maria Palasis Ph.D. CEO, President & Director 942.7k 1965 (60 Jahre)
Dr. Carmichael S. Roberts Jr., Ph.D. Co-Founder N/A 1969 (56 Jahre)
Mr. Jason Cavalier CFO, Treasurer & Secretary 464.11k 1973 (52 Jahr)
Mr. Ray Knox Vice President of Operations N/A
Ms. Vineeta Belanger Ph.D. Senior Vice President of Clinical Affairs N/A
Mr. Ronan P. O'Brien J.D. Chief Legal Officer 1973 (52 Jahr)
Dr. Robert Richard Ph.D. Senior Vice President of Technical Operations 1958 (67 Jahre)
Dr. Robert Kern M.D. Chief Clinical Advisor
Ms. Gloria Cosgrove Senior Vice President of Quality

Adresse: United States, Watertown. MA, 480 Arsenal Way - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://lyratherapeutics.com